Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 348 entries
View as:

ALN-APOC3 in Adult Participants With Dyslipidemia

Phase: N/A Priority: Normal
NCT ID: NCT06784349 Org: User:
Start: 01/27/25 End: 07/05/27 Due: 07/05/28

A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)

Phase: N/A Priority: Normal
NCT ID: NCT02407756 Org: User:
Start: 03/31/15 End: 03/31/16 Due: 03/31/17

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

Phase: N/A Priority: Normal
NCT ID: NCT03452228 Org: User:
Start: 06/07/18 End: 07/23/20 Due: 07/23/21

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Phase: N/A Priority: Normal
NCT ID: NCT05164250 Org: User:
Start: - End: - Due: -

Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

Phase: N/A Priority: Normal
NCT ID: NCT03156621 Org: User:
Start: 10/03/17 End: 02/13/20 Due: 02/13/21

Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04465487 Org: User:
Start: 10/05/20 End: 02/07/25 Due: 02/07/26

Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT02127801 Org: User:
Start: 10/31/14 End: 12/31/15 Due: 12/31/16

Study of Cemiplimab in Adults With Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03257267 Org: User:
Start: 09/05/17 End: 04/20/23 Due: 04/20/24

Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT05293678 Org: User:
Start: 04/12/22 End: 01/26/23 Due: 01/26/24

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06132191 Org: User:
Start: - End: - Due: -

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

Phase: N/A Priority: Normal
NCT ID: NCT01709513 Org: User:
Start: 09/30/12 End: 05/31/17 Due: 05/31/18

CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT04698187 Org: User:
Start: 03/11/21 End: 02/05/24 Due: 02/05/25

A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06669247 Org: User:
Start: 12/11/24 End: 09/30/35 Due: 09/30/36

COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT05092581 Org: User:
Start: 12/16/21 End: 06/09/22 Due: 06/09/23

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

Phase: N/A Priority: Normal
NCT ID: NCT03005782 Org: User:
Start: 11/07/16 End: 04/02/24 Due: 04/02/25

A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02651662 Org: User:
Start: 01/11/16 End: 12/25/26 Due: 12/25/27

A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain

Phase: N/A Priority: Normal
NCT ID: NCT00991172 Org: User:
Start: 11/30/09 End: 05/31/10 Due: 05/31/11

Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Phase: N/A Priority: Normal
NCT ID: NCT03564340 Org: User:
Start: 05/21/18 End: 06/21/26 Due: 06/21/27

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06230224 Org: User:
Start: 02/15/24 End: 05/14/27 Due: 05/14/28

A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee

Phase: N/A Priority: Normal
NCT ID: NCT00944892 Org: User:
Start: 08/31/09 End: 05/31/10 Due: 05/31/11

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05338892 Org: User:
Start: 06/22/22 End: 10/05/23 Due: 10/05/24

A Study of Tocilizumab in Patients With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01187563 Org: User:
Start: 08/31/10 End: 12/31/10 Due: 12/31/11

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

Phase: N/A Priority: Normal
NCT ID: NCT01521559 Org: User:
Start: 04/30/12 End: 03/31/14 Due: 03/31/15

Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

Phase: N/A Priority: Normal
NCT ID: NCT05131204 Org: User:
Start: 10/06/22 End: 07/12/23 Due: 07/12/24

REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure

Phase: N/A Priority: Normal
NCT ID: NCT05353166 Org: User:
Start: 06/30/22 End: 06/02/25 Due: 06/02/26